Antibody Therapeutics, Challenges & Opportunities
  • Byeong Doo Song
  • SLS Colloquia / 04.27.2017. 04:00 pm / Room N104, Bldg 110
Abstract

Antibody can be highly diverse and highly selective, thus making antibody an attractive drug candidate with good efficacy and low toxicity. Several key technological advances have led to the current success of antibody therapeutics. Using hybridoma technology OKT3, the first antibody drug made from mouse against CD-3, was introduced to the world in 1986. To reduce possible immunogenicity coming from mouse antibody sequence, chimerization and humanization technologies were developed. Ultimately human antibody sources were developed, namely various different types of human antibody libraries or transgenic mice with producing human antibodies. At the same time efforts to diversify antibody function were made including bisepcific antibody, antibody drug conjugate (ADC), immune checkpoint antibody, chimeric antigen receptor (CAR) T cell therapy. But still there are some challenges remaining to be overcome and innovative technologies will move antibody therapeutics forward.